ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Glycoscience firm Palleon launches

by Ryan Cross
October 16, 2017 | APPEARED IN VOLUME 95, ISSUE 41

Waltham, Mass.-based Palleon Pharmaceuticals has launched with $47.6 million in series A funding to develop immuno-oncology drugs based on cancer glycans—the sugar molecules that protrude from tumors and are used to avoid immune system surveillance. The approach is reminiscent of checkpoint inhibitor therapies, which jump-start the immune system’s ability to target tumors, but Palleon’s drugs will take aim at immune cell receptors that get misdirected by tumor glycans. Palleon’s scientific cofounders include Stanford University chemist Carolyn Bertozzi and University of Dundee glycoimmunologist Paul Crocker.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment